Unique Cellular and Biochemical Features of Human Mitochondrial Peroxiredoxin 3 Establish the Molecular Basis for Its Specific Reaction with Thiostrepton

A central hallmark of tumorigenesis is metabolic alterations that increase mitochondrial reactive oxygen species (mROS). In response, cancer cells upregulate their antioxidant capacity and redox-responsive signaling pathways. A promising chemotherapeutic approach is to increase ROS to levels incompatible with tumor cell survival. Mitochondrial peroxiredoxin 3 (PRX3) plays a significant role in detoxifying hydrogen peroxide (H2O2). PRX3 is a molecular target of thiostrepton (TS), a natural product and FDA-approved antibiotic. TS inactivates PRX3 by covalently adducting its two catalytic cysteine residues and crosslinking the homodimer. Using cellular models of malignant mesothelioma, we show here that PRX3 expression and mROS levels in cells correlate with sensitivity to TS and that TS reacts selectively with PRX3 relative to other PRX isoforms. Using recombinant PRXs 1–5, we demonstrate that TS preferentially reacts with a reduced thiolate in the PRX3 dimer at mitochondrial pH. We also show that partially oxidized PRX3 fully dissociates to dimers, while partially oxidized PRX1 and PRX2 remain largely decameric. The ability of TS to react with engineered dimers of PRX1 and PRX2 at mitochondrial pH, but inefficiently with wild-type decameric protein at cytoplasmic pH, supports a novel mechanism of action and explains the specificity of TS for PRX3. Thus, the unique structure and propensity of PRX3 to form dimers contribute to its increased sensitivity to TS-mediated inactivation, making PRX3 a promising target for prooxidant cancer therapy.

[1]  H. Sikes,et al.  Kinetic modeling of H2O2 dynamics in the mitochondria of HeLa cells , 2020, PLoS Comput. Biol..

[2]  T. Dick,et al.  Real-time monitoring of peroxiredoxin oligomerization dynamics in living cells , 2020, Proceedings of the National Academy of Sciences.

[3]  Min Suk Shim,et al.  Mitochondria-targeted drug delivery in cancers. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[4]  C. Furdui,et al.  Introduction to approaches and tools for the evaluation of protein cysteine oxidation. , 2020, Essays in biochemistry.

[5]  Joshua A. Bittker,et al.  Discovering the anticancer potential of non-oncology drugs by systematic viability profiling , 2020, Nature Cancer.

[6]  Dong-Seok Lee,et al.  Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression , 2019, International journal of molecular sciences.

[7]  W. Lowther,et al.  Aromatic Residues at the Dimer-Dimer Interface in the Peroxiredoxin Tsa1 Facilitate Decamer Formation and Biological Function. , 2019, Chemical research in toxicology.

[8]  Joshua E. Lewis,et al.  Peroxiredoxins in Cancer and Response to Radiation Therapies , 2019, Antioxidants.

[9]  V. Scalcon,et al.  Significance of the mitochondrial thioredoxin reductase in cancer cells: An update on role, targets and inhibitors , 2018, Free radical biology & medicine.

[10]  D. S. St. Clair,et al.  Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer. , 2018, Antioxidants & redox signaling.

[11]  W. Lowther,et al.  Novel hyperoxidation resistance motifs in 2-Cys peroxiredoxins , 2018, The Journal of Biological Chemistry.

[12]  J. Gerrard,et al.  Quaternary structure influences the peroxidase activity of peroxiredoxin 3. , 2018, Biochemical and biophysical research communications.

[13]  D. Barber,et al.  Cancer cell behaviors mediated by dysregulated pH dynamics at a glance , 2017, Journal of Cell Science.

[14]  W. Lowther,et al.  Kinetic analysis of structural influences on the susceptibility of peroxiredoxins 2 and 3 to hyperoxidation. , 2016, The Biochemical journal.

[15]  Edward T Chouchani,et al.  Disabling Mitochondrial Peroxide Metabolism via Combinatorial Targeting of Peroxiredoxin 3 as an Effective Therapeutic Approach for Malignant Mesothelioma , 2015, PloS one.

[16]  M. Murakami,et al.  How pH Modulates the Dimer-Decamer Interconversion of 2-Cys Peroxiredoxins from the Prx1 Subfamily* , 2015, The Journal of Biological Chemistry.

[17]  J. Reisz,et al.  Thiol‐blocking electrophiles interfere with labeling and detection of protein sulfenic acids , 2013, The FEBS journal.

[18]  T. Mak,et al.  Modulation of oxidative stress as an anticancer strategy , 2013, Nature Reviews Drug Discovery.

[19]  W. Lowther,et al.  Molecular Basis for the Resistance of Human Mitochondrial 2-Cys Peroxiredoxin 3 to Hyperoxidation* , 2013, The Journal of Biological Chemistry.

[20]  N. Heintz,et al.  Mitochondrial‐targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells , 2013, Journal of cellular physiology.

[21]  H. Pass,et al.  Peroxiredoxin 3 Is a Redox-Dependent Target of Thiostrepton in Malignant Mesothelioma Cells , 2012, PloS one.

[22]  G. Wondrak,et al.  Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes. , 2012, Biochemical pharmacology.

[23]  L. Poole,et al.  Kinetic and thermodynamic features reveal that Escherichia coli BCP is an unusually versatile peroxiredoxin. , 2011, Biochemistry.

[24]  P Andrew Karplus,et al.  Structural evidence that peroxiredoxin catalytic power is based on transition-state stabilization. , 2010, Journal of molecular biology.

[25]  W. Lowther,et al.  Protein Engineering of the Quaternary Sulfiredoxin·Peroxiredoxin Enzyme·Substrate Complex Reveals the Molecular Basis for Cysteine Sulfinic Acid Phosphorylation* , 2009, The Journal of Biological Chemistry.

[26]  N. Chandel,et al.  Reactive oxygen species-dependent signaling regulates cancer , 2009, Cellular and Molecular Life Sciences.

[27]  J. Pullar,et al.  Mitochondrial peroxiredoxin 3 is more resilient to hyperoxidation than cytoplasmic peroxiredoxins. , 2009, The Biochemical journal.

[28]  P. Karplus,et al.  Cysteine pK(a) values for the bacterial peroxiredoxin AhpC. , 2008, Biochemistry.

[29]  M. Murphy,et al.  Targeting lipophilic cations to mitochondria. , 2008, Biochimica et biophysica acta.

[30]  C. Winterbourn,et al.  Reconciling the chemistry and biology of reactive oxygen species. , 2008, Nature chemical biology.

[31]  N. Doudican,et al.  Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism , 2008, Cancer Chemotherapy and Pharmacology.

[32]  W. Lowther,et al.  Structure of the sulphiredoxin–peroxiredoxin complex reveals an essential repair embrace , 2008, Nature.

[33]  N. Brot,et al.  Free methionine-(R)-sulfoxide reductase from Escherichia coli reveals a new GAF domain function , 2007, Proceedings of the National Academy of Sciences.

[34]  N. Isaacs,et al.  Bovine mitochondrial peroxiredoxin III forms a two-ring catenane. , 2005, Structure.

[35]  P. Karplus,et al.  Analysis of the link between enzymatic activity and oligomeric state in AhpC, a bacterial peroxiredoxin. , 2005, Biochemistry.

[36]  J. Jacquot,et al.  Effect of pH on the oxidation-reduction properties of thioredoxins. , 2003, Biochemistry.

[37]  P. Karplus,et al.  Peroxiredoxin Evolution and the Regulation of Hydrogen Peroxide Signaling , 2003, Science.

[38]  Y. Soini,et al.  Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma , 2002, The Journal of pathology.

[39]  Robin A. J. Smith,et al.  Drug delivery to mitochondria: the key to mitochondrial medicine. , 2000, Advanced drug delivery reviews.

[40]  Joan C. Han,et al.  A procedure for quantitative determination of tris(2-carboxyethyl)phosphine, an odorless reducing agent more stable and effective than dithiothreitol. , 1994, Analytical biochemistry.

[41]  W. de Souza,et al.  The mitochondrion of Trypanosoma cruzi is a target of crystal violet toxicity. , 1989, Molecular and biochemical parasitology.

[42]  C. Winterbourn,et al.  Hyperoxidation of peroxiredoxins 2 and 3: Rate constants for the reactions of the sulfenic acid of the peroxidatic cysteine , 2013 .